Efficacy and safety of Qingpeng ointment for acute gouty arthritis: a multi-center, randomized, double-blind, placebo-controlled trial

Beijing University of Chinese Medicine0 个研究点目标入组 203 人开始时间: 2021年1月25日最近更新: 2024年1月22日

适应症

试验速览

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35549757/ (added 16/05/2022) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38178115/ (added 08/01/2024)

•1. Patients who meet the ACR (American College of Rheumatology)/EULAR (European League Against Rheumatism) gout classification criteria
•2. Patients with joint pain intensity score (VAS, 0-10 points) =3 points
•3. Patients with an acute flare of gout, the time from the onset to the visit to hospital should not exceed 1 week
•4. Patients aged between 18 to 65 years old
•5. Patients who are volunteer to participate in the study and sign the informed consent

•1. Patients who also suffer from other types of arthritis
•2. Patients who are allergic to the study drugs (Qingpeng Ointment, DSSRT)
•3. Patients suffering from severe cardiovascular, cerebrovascular, liver, and kidney diseases
•4. Patients suffering from mental diseases and senile dementia
•5. Women during pregnancy and lactation
•6. Patients with skin ulceration at the affected joint(s)
•7. Patients who have newly added uric acid-lowering drugs for any reason in the past week
•8. Patients who participate in other clinical trials at the same time

发起方

Beijing University of Chinese Medicine